Introduction
Diabetes is a major public health problem globally and detecting those who have a high probability of developing type 2 diabetes is a priority, so that prevention programs can be proposed to people at greatest risk [1] . Indeed, throughout the world the number of people with diabetes is projected to increase to 439 million in 2030 from 285 million in 2010 [2] .
Several studies have tried to characterise those with a high risk of developing diabetes using HbA1c, fasting plasma glucose (FPG) and 2-h plasma glucose (2hPG) following an oral glucose tolerance test (OGTT) [3, 4] . FPG is the least expensive of these three measures of glycaemia, but it does require that individuals are fasting. An OGTT is time-consuming and more expensive. An advantage of HbA1c is that individuals need not be fasting [5] . Although HbA1c can be distorted by some diseases such as iron deficiency anaemia [6] , the assay has several advantages such as a low intra-individual variability in non-diabetic people, [7] and the International Federation for Clinical Chemistry (IFCC) now has a method to standardize this assay, in order to overcome some of the differences between laboratories [8, 9] .
Three hyperglycaemic states have been defined to indicate a risk of diabetes: HbA1c between 5.7 and 6.4%, impaired fasting glucose (IFG, FPG between 5.6 and 6.9 mmol/l) and impaired glucose tolerance (IGT, 2hPG between 7.8 and 11.0 mmol/l) [10] . In 2009, an Expert Committee indicated that people with an HbA1c between 6.0% and 6.4% were at risk for diabetes [11] ; the 6.0% threshold was later lowered in the American Diabetes Association (ADA) recommendations to 5.7% in 2010 [10] . The lower limit of IFG was decreased in 2003 from 6.1 to 5.6 mmol/l by an ADA International Expert Committee [12] . While there are a number of studies that show there is an increased risk of diabetes for those with IGT and IFG [13] , there has not been a search for more precise thresholds for these categories, nor for HbA1c. Indeed, the 2003 change in the definition of IFG has been disputed [14] .
The oral glucose tolerance test is rarely used in clinical practice and we define diabetes in this article by either FPG ≥ 7.0 mmol/l and/or HbA1c ≥ 6.5%, as this combination is likely to be used in clinical practice, as proposed in other publications [15, 16] . However, we have also included diabetes defined additionally by 2hPG ≥ 11.1 mmol/l, to evaluate possible changes in FPG and HbA1c thresholds.
We use epidemiologic studies from three countries: Denmark, Australia and France, the prospective cohorts: Inter99, AusDiab (Australian Diabetes, Obesity and Lifestyle Study) and D.E.S.I.R. (Data from an Epidemiological Study on the Insulin Resistance syndrome) to determine whether there are thresholds or change-points for HbA1c, FPG and 2hPG, above which the incidence of diabetes increases at a significantly higher rate than below this change-point. Thresholds are characterised by their sensitivity, specificity, positive and negative predictive values for incident type 2 diabetes.
_________________________________________________________________________________

Materials and methods
Inter99 is a Danish longitudinal study set up to evaluate whether individual intervention on life style factors (smoking, physical activity and unhealthy diet) can prevent cardiovascular disease and type 2 diabetes [17] . In 1999-2001, 13,016 individuals, 30-60 years, were randomly selected from the civil register in south western Copenhagen County, after stratification on age and sex [17] . Of the 6, 906 who participated at the baseline examination, 122 were excluded: 99 for the language barrier and 23 for abuse of drugs or alcohol [17] . Among the 6784 eligible subjects (53% participation), 5228 attended the follow-up exam at five years. We excluded from our analyses: treated diabetic patients at baseline (64 were on insulin or oral drugs), those with missing HbA1c at baseline (n=5), missing FPG at baseline (n=23) or at follow-up respectively (n=30 then n=7). At baseline, 169 participants had diabetes defined by FPG ≥ 7.0 mmol/l and/or HbA1c after standardisation ≥ 6.5% and they have also been excluded. We analysed data from the 4930 participants without diabetes at baseline. When 2hPG was additionally studied, 4592 individuals were followed. HbA1c was assayed by ion-exchange high performance liquid chromatography technique (Bio-Rad variant) and values were DCCT-UKPDS aligned. Plasma venous glucose were assayed by the hexokinase/G6PD method (Boehringer Mannheim) [17] . Baseline body mass index (BMI) was evaluated in lightly clad participants.
AusDiab included 11,247 participants in 1999-2000 [18] . The selection of households was made by cluster sampling, stratified on the six States and the Northern Territory of Australia, and six census collectors' districts were randomly selected in each stratum; 17,129 households were eligible but only 11,479 responded to the interview, 11,247 individuals underwent biomedical examinations and 10,916 were eligible [18] . In 2004-2005, five years after inclusion, 6537 of the eligible subjects participated in the follow-up [19] . For analyses, among the 6378 non-diabetic subjects (159 had diabetes treatment), we excluded 44 subjects with missing HbA1c at baseline then 77 with missing HbA1c at follow-up; There was no missing data for FPG at baseline and among remaining subjects, we deleted 46 with missing FPG at follow-up. We studied the 6012 non-diabetic participants aged between 25 and 88 years (199 participants were identified as diabetic at baseline by FPG ≥ 7.0 mmol/l and/or HbA1c ≥ 6.5% after standardisation). When diabetes was additionally defined by 2hPG, 5704 individuals were studied. The variables measured were the same as in Inter99, however, the techniques of glucose and HbA1c assays were different. HbA1c was obtained by determining total glycated hemoglobin with high-performance liquid chromatography (Bio-Rad VARIANT hemoglobin testing system) then an algorithm was used to provide standardized HbA1c [19] . FPG was measured by the glucose oxidase method at baseline and hexokinase method at follow-up [19] . BMI was evaluated at baseline.
D.E.S.I.R. is a prospective study on the insulin resistance syndrome [3] . From the 5212 volunteers who participated, 4111 subjects were followed six years. We excluded from analyses: treated diabetic patients at baseline (n=44) and subjects without information on treatment at baseline (n=9) or at follow-up (n=122). We deleted subjects with missing baseline HbA1c (n=7), missing baseline FPG (n=5), missing HbA1c then FPG at follow-up (n=56, n=9) and finally 75 participants with baseline FPG ≥ 7.0 mmol/l and/or baseline HbA1c ≥ 6.5%. We used baseline data from 3784 men and women aged between 30 and 65 years. In D.E.S.I.R. the 2hPG was not available. HbA1c was measured by High Performance liquid chromatography with Bio-Rad aligned to DCTT-UKPDS standards and FPG by an enzymatic method (glucose oxidase/ peroxydase) with a Technicon RA 1000 automated analyser (Bayer) or a Specific or a Delta (Konelab) [3] . BMI was also evaluated at baseline.
Definitions
Diabetes was defined at baseline and at follow-up by treatment for diabetes &/or FPG ≥ 7.0 mmol/l &/or HbA1c ≥ 6.5% (after standardization).
Three other definitions of diabetes were also used to evaluate the stability of the change-points: 
Statistical Methods
For each study, the characteristics of participants who developed and did not develop diabetes are described and compared between studies, using a  2 test for categorical variables and mean age, BMI and glycaemic parameters were compared by ANOVA.
As the HbA1c distributions differed between cohorts (Fig. 1A) , and according to baseline FPG (Fig. 2C ), and they were modelled by logistic regression. We sought change-points beyond which the incidence of diabetes increased significantly for FPG and HbA1c, in separate models, and then in the same model; the likelihoods of the change point-models were compared with the likelihoods of simple linear models, using the ² distribution [20] . The 95%
confidence intervals for the change-points were constructed by identifying the change-points corresponding to the 2.5% and 97.5% values of the ² distribution.
The stability of the change-points was studied when diabetes was defined according to the three other definitions of diabetes given above; for the first two definitions, the baseline population The SAS software version 9.1.3 was used for statistical analyses. Table 1 ).
The incidences of diabetes were: 2.3% for Inter99, 3.1% for AusDiab both over 5 years and 2.4% for D.E.S.I.R. over 6 years with different percentages with diabetes screened by treatment, FPG alone, HbA1c alone or both HbA1c and FPG (Table 1 ). Incidences increased with increasing baseline HbA1c, but the actual incidence at any given value of HbA1c differed between cohorts ( Fig. 2A ).
However, after HbA1c standardization, the diabetes incidence curves were more similar (Fig. 2B ).
Change-points were present at 5.1% (Inter99) HbA1c definition (6.4%). For Inter99, the change points varied from 5.1 to 5.9%. In AusDiab, the FPG change-point for predicting incident diabetes was the same whatever the diabetes definition (5.5 mmol/l); there were many cases for the two other cohorts when no change-point was detected. In particular, when the diabetes definition included 2hPG, the HbA1c changes points increased for both
Inter99 and AusDiab, but for FPG, the change point was higher for Inter99, identical for AusDiab. For 2hPG a threshold of 9.9 mmol/l was found in AusDiab, but no change-point was detected in Inter99. were lower for this second combination of thresholds than for the first combination.
________________________________________________________________________________
Discussion
We found change-points above which the incidence of diabetes began to increase significantly in Positive predictive values showed a similar increase for all three cohorts, with a three to four fold increase for an HbA1c of 6.0% in comparison to 5.5% and a two to three fold increase for FPG at 6.0 mmol/l in comparison to 5.5 mmol/l. Positive predictive values for predicting diabetes were higher when we used both HbA1c & FPG than when we used HbA1c &/or FPG. Thus while the change-point method identified thresholds where the incidences increased, the absolute increase in positive predictive values at these points was not large. The negative predictive values were always close to 100%, while sensitivity was always higher than specificity for the currently recommended thresholds for hyperglycaemia of 5.6 mmol/l for FPG, while specificity was higher than sensitivity for HbA1c at 5.7%.
We explored separately data from three large studies (Danish, Australian and French) with a monitoring period of at least five years: the follow-up period was the same for Inter99 and AusDiab (5 years), one year more for D.E.S.I.R. (6 years). Among the limitations of our study, Inter99 is population-based, with a 53% acceptance to participate at baseline and two thirds were then followed;
in AusDiab, 55% of invited participants underwent a biomedical examination at baseline, and then 58% of these were followed [19] ; the D.E.S.I.R. cohort is not population-based, but 70% of the participants were able to be followed. There were differences in the three cohorts between those followed and not-followed, for at least one of the characteristics: gender, age, HbA1c, FPG, 2hPG or BMI, thus the studied population differed from that at inclusion (data not shown), however these differences while statistically significant, were minor. Another limitation is that the assay techniques used to measure HbA1c and plasma glucose were not the same in the three studies. All three HbA1c assays were DCCT-UKPDS aligned but as the distributions of HbA1c differed between the three cohorts, we standardised HbA1c measures on the D.E.S.I.R. study, after taking into account the age, sex and BMI differences in the three cohorts. Thus we are assuming that the basic distribution of
HbA1c is identical in all three populations, after taking into account age, sex and BMI, and that the observed differences between HbA1c distributions were due to differences in the assays.
Other published studies have also analysed HbA1c and incident diabetes. Edelman et al.
found that diabetes incidence was 2.5% per year for HbA1c between 5.6% and 6.0% [21] . The Expert Committee defined individuals with an HbA1c between 6.0% and 6.5% as being at high risk of diabetes [11] ; subsequently, in January 2010 a new threshold of 5.7% was published in the ADA recommendations [10] . A recent study of Caucasian Europeans proposed that the most appropriate cut-point, using receiver operating characteristic (ROC) curves for the identification of IFG or IGT, was 5.8% [22] . The limits found by the change-point method in our analyses were lower (5.1% in Inter99, 2 mmol/l using again, the criteria of maximizing sensitivity and specificity [25] . In our three studies, the 6.0 mmol/l threshold had a two to three fold higher positive predictive value than 5.5 mmol/l, whereas the positive predictive values for lower FPG values were similar.
We have not studied the 'optimum' thresholds, from sensitivity and specificity analyses; this maximisation is inappropriate as in screening for diabetes, and identifying those at risk of diabetes, the sensitivity is more important than the specificity. The change-point method provided different values in the three populations, and the confidence intervals were very wide. We believe that the positive predictive value may be the more appropriate metric to identify thresholds. Even though the positive predictive value is dependent on the basic incidence of diabetes in each population, it increased similarly for all cohorts, for both parameters: HbA1c and FPG.
Inoe et al. [26] analysed data from 10 042 Japanese men and women with a follow-up period of 5.5 years and baseline FPG < 7.0 mmol/l; they found that the cumulative incidence of diabetes was more than 2.0% for HbA1c between 5.5% and 6.4%. The use of HbA1c would have allowed the identification of people with a higher diabetes risk that would not have been detected by FPG alone.
The 5.5% threshold was close to the change-points that we found (5.4% for AusDiab, 5.3% for D.E.S.I.R.). Inoue et al. also sought the cumulative incidence of diabetes among subjects with IFG who had HbA1c between 5.5% and 6.4%; it was 25%, higher than the cumulative incidence in those with IFG and HbA1c <5.5% (7.6%) [26] .
Other studies analysed HbA1c according to ethnicity. The Third National Health and Nutrition Examination Survey data the U.S. found that the distribution of HbA1c differed between races; the mean HbA1c for non-treated individuals was higher in black non-Hispanic than in Mexican-Americans and lower in non-Hispanic whites [27] .
We have previously studied incident diabetes, where diabetes was defined by treatment and/or HbA1c ≥ 6.5% [28] . In strictly non-diabetic subjects, those with HbA1c < 6.5% and 0.84, 0.91 and 0.82 for Inter99, AusDiab and D.E.S.I.R. respectively, indicating that HbA1c was able to discriminate incident diabetes as defined by HbA1c [28] .
For HbA1c, while the three studies showed similar incidence curves, the HbA1c distributions differed considerably. The need for standardization of the HbA1c assay, so that it is more closely aligned to the DCCT-UKPDS standard, and better to the IFCC standard, is necessary if HbA1c is to be used as a diagnostic criterion for diabetes. The ADA recommendation states explicitly that the HbA1c assay should be standardized [8, 9] .
In conclusion, our results show that both HbA1c and FPG predict diabetes, defined on the 
